Akebia Therapeutics Reports Director/Officer Changes & Shareholder Votes
Ticker: AKBA · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1517022
| Field | Detail |
|---|---|
| Company | Akebia Therapeutics, Inc. (AKBA) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, governance, shareholder-vote
Related Tickers: AKBA
TL;DR
Akebia's leadership team is changing, and they're holding a shareholder vote.
AI Summary
Akebia Therapeutics, Inc. filed an 8-K on June 13, 2025, reporting events as of June 10, 2025. The filing indicates changes related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. It also covers the submission of matters to a vote of security holders.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with shareholder votes, can indicate internal shifts or strategic decisions that may carry inherent risks.
Key Numbers
- 001-36352 — SEC File Number (Identifies the specific filing for Akebia Therapeutics, Inc.)
- 20-8756903 — IRS Employer Identification No. (Tax identification number for Akebia Therapeutics, Inc.)
Key Players & Entities
- Akebia Therapeutics, Inc. (company) — Registrant
- June 10, 2025 (date) — Date of earliest event reported
- June 13, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 245 First Street Cambridge, Massachusetts 02142 (address) — Principal executive offices
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, election of directors, and appointment of certain officers, as well as compensatory arrangements for certain officers.
What is the exact date of the events reported in this 8-K?
The date of the earliest event reported is June 10, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 245 First Street, Cambridge, Massachusetts 02142.
What other type of corporate action is reported in this filing?
The filing also reports the submission of matters to a vote of security holders.
When was this 8-K form filed with the SEC?
This 8-K form was filed as of June 13, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding Akebia Therapeutics, Inc. (AKBA).